On or around 12/09/2019 (Date of last review)
Filing Date: April 15, 2019
According to the Complaint, Teligent researches, develops, produces, supplies, and sells generic pharmaceutical products.
The Complaint alleges that during the Class Period, Defendants violated provisions of the Exchange Act by issuing false and misleading statements to investors, including in filings with the U.S. Securities and Exchange Commission (“SEC”). The Complaint alleges that specifically, Defendants made false and/or misleading statements regarding, and/or failed to disclose, product non-conformities in research and development and non-compliance with applicable regulations.
On July 1, 2019, the Court issued an Order appointing Lead Plaintiff and Counsel. Lead Plaintiff filed an amended Complaint on September 13. On December 9, Lead Plaintiff filed a second amended Complaint.
Company & Securities Information
Defendant: Teligent, Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: TLGT
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Mo-Kan Iron Workers Pension Fund, et al. v. Teligent, Inc., et al.